Venturi Wealth Management LLC Takes $131,000 Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Venturi Wealth Management LLC bought a new stake in Blueprint Medicines Co. (NASDAQ:BPMC) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,500 shares of the biotechnology company’s stock, valued at approximately $131,000.

Other institutional investors have also modified their holdings of the company. Empirical Asset Management LLC acquired a new position in shares of Blueprint Medicines in the 4th quarter valued at $2,348,000. Stephens Inc. AR acquired a new position in Blueprint Medicines in the 4th quarter valued at $321,000. Massachusetts Financial Services Co. MA increased its stake in Blueprint Medicines by 48.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after buying an additional 82,693 shares during the period. Entropy Technologies LP acquired a new position in Blueprint Medicines in the 3rd quarter valued at $999,000. Finally, KBC Group NV increased its stake in Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,023 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Piper Sandler upped their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. JPMorgan Chase & Co. increased their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Wedbush reissued an “outperform” rating and issued a $128.00 target price (up from $124.00) on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, Stephens restated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $123.83.

Blueprint Medicines Price Performance

Blueprint Medicines stock opened at $92.25 on Friday. The firm has a market capitalization of $5.90 billion, a P/E ratio of -85.42 and a beta of 0.62. Blueprint Medicines Co. has a 1 year low of $80.42 and a 1 year high of $121.90. The business has a 50-day moving average of $99.55 and a 200-day moving average of $94.40. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Activity

In other Blueprint Medicines news, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the sale, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the transaction, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock worth $4,984,696 in the last 90 days. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.